Theracea Pharma LC
Tucson, AZ
- UEI
- KSNLTEALRQL5
- CAGE
- 89EB8
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 6196 N Corte San Bella, Tucson, AZ 85741, USA
- Website
- theracea.com
- Founded
- 2019
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
About the company
Theracea Pharma LC is a for-profit limited liability company registered in the System for Award Management (SAM) since March 2019, with a registration valid through January 2025. The company specializes in advanced medical diagnostic technologies, particularly focusing on developing innovative radiotracer and imaging technologies for medical research and clinical applications. As a small business engaged in scientific innovation, Theracea Pharma LC has positioned itself as a research-driven enterprise working at the intersection of chemistry, biology, and medical imaging technologies.
The company has consistently received federal grants from civilian agencies, primarily the National Science Foundation (NSF) and the National Institute of Biomedical Imaging and Bioenginering, to develop sophisticated positron emission tomography (PET) diagnostic agents and imaging technologies. Specifically, Theracea Pharma LC has been awarded multiple Small Business Innovation Research (SBIR) Phase I grants totaling over $500,000, focusing on developing 18F-radiotracer kits and advanced bioconjugation methodologies for PET imaging. Their most recent NSF grant, awarded in September 2024 for $275,000, aims to create innovative diagnostic tools for detecting biomarkers, with particular emphasis on oncology applications. The projects involve developing cutting-edge chemical synthesis methods for preparing fluorine-18 labeled biomolecules, which can assist researchers and physicians in more precisely selecting and assessing therapies, especially in cancer treatment. These grants underscore the company's commitment to translating scientific discoveries into commercially viable technologies that address critical healthcare challenges.
Quick answers
Is Theracea Pharma LC registered in SAM.gov?
Yes. Theracea Pharma LC's SAM.gov registration is active through January 21, 2027.
What is Theracea Pharma LC's most recent federal award?
Theracea Pharma LC's most recent federal grant award is Sbir phase i: development of 18F-radiotracer kits for detection of biomarkers by positron emission tomography (2423679), from National Science Foundation, on September 1, 2024.
On GovTribe
See Theracea Pharma LC's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors